Abstract
In the past 5 years much progress has been made in understanding the molecular basis of Crohn's disease, a multifactorial chronic inflammatory disease of the gastrointestinal tract. Data suggest that hampered autophagy—the major lysosomal pathway for recycling of cytoplasmic material—might contribute to an increased susceptibility to Crohn's disease. Consequently, intense investigations have started to evaluate the potential value of autophagy as a therapeutic target and as a highly needed diagnostic tool. Interestingly, as well as the promising introduction of direct autophagic modulators, several drugs already used in the treatment of Crohn's disease might exert at least part of their effect through the regulation of autophagy. However, whether this phenomenon contributes to or rather counteracts their therapeutic use, remains to be determined and might prove to be highly compound-specific. Here we review the complex and emerging role of autophagy modulation in the battle against Crohn's disease. Moreover, we discuss the potential benefits and deleterious effects of autophagic regulation by both new and clinically used drugs.
Key Points
-
Crohn's disease is a multifactorial chronic inflammatory disease of the gastrointestinal tract for which the exact causative mechanism is still unknown
-
Current treatment options for Crohn's disease are far from successful in all patients, indicating the urgent need for more efficient diagnostic and therapeutic strategies
-
Polymorphisms in autophagy-related genes have been associated with the incidence of Crohn's disease
-
Autophagy is an important regulator of both innate and adaptive immune and/or inflammatory responses and is an appealing target to restore and normalize the imbalanced inflammatory responses in Crohn's disease
-
Several compounds currently used in treatment of Crohn's disease, such as anti-TNF agents, thiopurines and curcumin, have been shown to affect autophagy or might benefit from combinatory autophagy stimulation (for example, with sirolimus)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118–1125 (2010).
Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955–962 (2008).
Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207–211 (2007).
Parkes, M. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39, 830–832 (2007).
Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603–606 (2001).
Henckaerts, L. et al. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. Inflamm. Bowel Dis. 17, 1392–1397 (2011).
Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728–741 (2011).
Choi, A. M., Ryter, S. W. & Levine, B. Autophagy in human health and disease. N. Engl. J. Med. 368, 651–662 (2013).
Kuballa, P., Nolte, W. M., Castoreno, A. B. & Xavier, R. J. Autophagy and the immune system. Annu. Rev. Immunol. 30, 611–646 (2012).
Deretic, V. Autophagy as an innate immunity paradigm: expanding the scope and repertoire of pattern recognition receptors. Curr. Opin. Immunol. 24, 21–31 (2012).
Orvedahl, A. et al. Autophagy protects against Sindbis virus infection of the central nervous system. Cell Host Microbe 7, 115–127 (2010).
Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150, 803–815 (2012).
Dupont, N. et al. Shigella phagocytic vacuolar membrane remnants participate in the cellular response to pathogen invasion and are regulated by autophagy. Cell Host Microbe 6, 137–149 (2009).
Yoshikawa, Y. et al. Listeria monocytogenes ActA-mediated escape from autophagic recognition. Nat. Cell Biol. 11, 1233–1240 (2009).
Thurston, T. L., Wandel, M. P., von Muhlinen, N., Foeglein, A. & Randow, F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature 482, 414–418 (2012).
Alonso, S., Pethe, K., Russell, D. G. & Purdy, G. E. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc. Natl Acad. Sci. USA 104, 6031–6036 (2007).
Ponpuak, M. et al. Delivery of cytosolic components by autophagic adaptor protein p62 endows autophagosomes with unique antimicrobial properties. Immunity 32, 329–341 (2010).
Kim, B. H. et al. A family of IFN-γ-inducible 65-kD GTPases protects against bacterial infection. Science 332, 717–721 (2011).
Xu, Y. et al. Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27, 135–144 (2007).
Delgado, M. A., Elmaoued, R. A., Davis, A. S., Kyei, G. & Deretic, V. Toll-like receptors control autophagy. EMBO J. 27, 1110–1121 (2008).
Shi, C. S. & Kehrl, J. H. MyD88 and Trif target Beclin 1 to trigger autophagy in macrophages. J. Biol. Chem. 283, 33175–33182 (2008).
de Vries, H. S. et al. Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease. PLoS One 4, e7818 (2009).
Iliev, I. D. et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336, 1314–1317 (2012).
Lee, H. K., Lund, J. M., Ramanathan, B., Mizushima, N. & Iwasaki, A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315, 1398–1401 (2007).
Rathinam, V. A., Vanaja, S. K. & Fitzgerald, K. A. Regulation of inflammasome signaling. Nat. Immunol. 13, 333–2 (2012).
Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264–268 (2008).
Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).
Manjithaya, R., Anjard, C., Loomis, W. F. & Subramani, S. Unconventional secretion of Pichia pastoris Acb1 is dependent on GRASP protein, peroxisomal functions, and autophagosome formation. J. Cell Biol. 188, 537–546 (2010).
Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011).
Dupont, N. et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J. 30, 4701–4711 (2011).
Shi, C. S. et al. Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255–263 (2012).
Plantinga, T. S. et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 60, 1229–1235 (2011).
Harris, J. et al. Autophagy controls IL-1β secretion by targeting pro-IL-1β for degradation. J. Biol. Chem. 286, 9587–9597 (2011).
Nedjic, J., Aichinger, M., Emmerich, J., Mizushima, N. & Klein, L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature 455, 396–400 (2008).
McLeod, I. X., Jia, W. & He, Y. W. The contribution of autophagy to lymphocyte survival and homeostasis. Immunol. Rev. 249, 195–204 (2012).
Strisciuglio, C. et al. Impaired autophagy leads to abnormal dendritic cell-epithelial cell interactions. J. Crohns Colitis http://dx.doi.org/10.1016/j.crohns.2012.08.009.
Wildenberg, M. E. et al. Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. Gastroenterology 142, 1493–1503 (2012).
Connor, A. M., Mahomed, N., Gandhi, R., Keystone, E. C. & Berger, S. A. TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. Arthritis Res. Ther. 14, R62 (2012).
Keller, C. W. et al. TNF-α induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J. Biol. Chem. 286, 3970–3980 (2011).
Jia, G., Cheng, G., Gangahar, D. M. & Agrawal, D. K. Insulin-like growth factor-1 and TNF- α regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol. Cell Biol. 84, 448–454 (2006).
Harris, J. & Keane, J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161, 1–9 (2010).
Castillo, E. F. et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc. Natl Acad. Sci. USA 109, E3168–E3176 (2012).
Saito, M. et al. Intestinal epithelial cells with impaired autophagy lose their adhesive capacity in the presence of TNF-α. Dig. Dis. Sci. 57, 2022–2030 (2012).
Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774–1785 (2003).
Wildenberg, M. et al. ATG16L1 genotype is associated with response to anti-TNF in vitro [abstract P668]. J. Crohns Colitis 7 (Suppl. 1), S279 (2013).
Guijarro, L. G., Roman, I. D., Fernandez-Moreno, D., Gisbert, J. P. & Hernandez-Breijo, B. Is the autophagy induced by thiopurines beneficial or deleterious? Curr. Drug Metab. 13, 1267–1276 (2012).
Petit, E. et al. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 22, 632–642 (2008).
Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. Mol. Cell 40, 280–293 (2010).
Zhou, S. et al. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde? Cancer Lett. 323, 115–127 (2012).
Hilsden, R. J., Verhoef, M. J., Rasmussen, H., Porcino, A. & deBruyn, J. C. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 655–662 (2011).
Ali, T., Shakir, F. & Morton, J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion 85, 249–255 (2012).
Ramsewak, R. S., DeWitt, D. L. & Nair, M. G. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I–III from Curcuma longa. Phytomedicine 7, 303–308 (2000).
Ruby, A. J., Kuttan, G., Babu, K. D., Rajasekharan, K. N. & Kuttan, R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 94, 79–83 (1995).
Aggarwal, B. B. & Harikumar, K. B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 41, 40–59 (2009).
Negi, P. S., Jayaprakasha, G. K., Jagan Mohan, R. L. & Sakariah, K. K. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J. Agric. Food Chem. 47, 4297–4300 (1999).
Yadav, V. R., Suresh, S., Devi, K. & Yadav, S. Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS PharmSciTech. 10, 752–762 (2009).
Han, J. et al. Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy 8, 812–825 (2012).
Alavez, S., Vantipalli, M. C., Zucker, D. J., Klang, I. M. & Lithgow, G. J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472, 226–229 (2011).
Totino, P. R., Daniel-Ribeiro, C. T., Corte-Real, S. & de Fatima Ferreira-da-Cruz, M. Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp. Parasitol. 118, 478–486 (2008).
Solomon, V. R. & Lee, H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 625, 220–233 (2009).
Ferrer, I. R., Araki, K. & Ford, M. L. Paradoxical aspects of rapamycin immunobiology in transplantation. Am. J. Transplant. 11, 654–659 (2011).
Louis, E. & Belaiche, J. Hydroxychloroquine (Plaquenil) for recurrence prevention of Crohn's disease after curative surgery. Gastroenterol. Clin. Biol. 19, 233–234 (1995).
Glinsky, G. V. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle 7, 3564–3576 (2008).
Massey, D. C., Bredin, F. & Parkes, M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57, 1294–1296 (2008).
Yang, K. & Chi, H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin. Immunol. 24, 421–428 (2013).
Nakagawa, S., Nishihara, K., Inui, K. & Masuda, S. Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. Eur. J. Pharmacol. 696, 143–154 (2012).
Bruyn, G. A. et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Ann. Rheum. Dis. 67, 1090–1095 (2008).
Reinisch, W. et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am. J. Gastroenterol. 103, 2284–2292 (2008).
Garcia-Maurino, S., Alcaide, A. & Dominguez, C. Pharmacological control of autophagy: therapeutic perspectives in inflammatory bowel disease and colorectal cancer. Curr. Pharm. Des 18, 3853–3873 (2012).
Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259–263 (2008).
Vermeire, S. Towards a novel molecular classification of IBD. Dig. Dis. 30, 425–427 (2012).
Dubinsky, M. C. et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100, 2239–2247 (2005).
Rutgeerts, P., Vermeire, S. & Van, A. G. Biological therapies for inflammatory bowel diseases. Gastroenterology 136, 1182–1197 (2009).
Li, F., Wang, L., Burgess, R. J. & Weinshilboum, R. M. Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet. Genomics 18, 1083–1094 (2008).
Weersma, R. K. & Wijmenga, C. Using genetic information for the identification, classification and treatment of Crohn's disease: are we there yet? Expert. Rev. Gastroenterol. Hepatol. 2, 719–721 (2008).
Cuffari, C. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. World J. Pediatr. 6, 203–209 (2010).
Vermeire, S. Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment. Pharmacol. Ther. 24 (Suppl. 3), 2–10 (2006).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401–410 (2012).
De Cassan, C., Fiorino, G. & Danese, S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig. Dis. 30, 368–375 (2012).
Baert, F. et al. Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59, 304–314 (2004).
Van Assche, G., Vermeire, S. & Rutgeerts, P. The potential for disease modification in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7, 79–85 (2010).
Magro, F. & Portela, F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 24 (Suppl. 1), 3–14 (2010).
Perrier, C. & Rutgeerts, P. New drug therapies on the horizon for IBD. Dig. Dis. 30 (Suppl. 1), 100–105 (2012).
Acknowledgements
This work of the authors is supported by project grants from the Fund for Scientific Research Flanders (FWO-Vlaanderen, G072810N, G058412N and G060713N to P. Agostinis) and from GOA grants (GOA/11/015 to S. Vermeire and GOA/11/2010-2015 to P. Agostinis).
Author information
Authors and Affiliations
Contributions
K. Nys contributed to all aspects of the preparation of this manuscript. S. Vermeire contributed to researching data, discussion of content and reviewing/editing the manuscript before submission. P. Agostinis contributed to discussion of content and reviewing/editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nys, K., Agostinis, P. & Vermeire, S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease?. Nat Rev Gastroenterol Hepatol 10, 395–401 (2013). https://doi.org/10.1038/nrgastro.2013.66
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.66
This article is cited by
-
Patient experiences with the role of physical activity in inflammatory bowel disease: results from a survey and interviews
BMC Gastroenterology (2021)
-
DNA Damage-Regulated Autophagy Modulator 1 (DRAM1) Mediates Autophagy and Apoptosis of Intestinal Epithelial Cells in Inflammatory Bowel Disease
Digestive Diseases and Sciences (2021)
-
Körperliche Aktivität, Bewegung und Sport bei chronisch-entzündlichen Darmerkrankungen
Journal für Gastroenterologische und Hepatologische Erkrankungen (2018)
-
Mesenchymal Stromal Cells Derived From Crohn's Patients Deploy Indoleamine 2,3-dioxygenase-mediated Immune Suppression, Independent of Autophagy
Molecular Therapy (2015)
-
Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease
Clinical and Translational Gastroenterology (2015)